When ADAM9 was knocked out or the specific targeting monoclonal antibody (RAV-18) was used, gastric cancer cell proliferation and invasion could be inhibited in cells that were originally at high levels of ADAM9 expression. The gene discussed is ADAM9; the disease is gastric cancer.